Regulatory Filings • Jan 9, 2024
Regulatory Filings
Open in ViewerOpens in native device viewer
Washington, D.C. 20549
OMB APPROVAL
| OMB Number: | 3235-0287 |
|---|---|
| Estimated average burden hours | |
| per response | 0.5 |
Check this box if no longer subject to
Instruction 1(b).
Section 16. Form 4 or
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
| 1. Name and Address of Reporting Person Rozov Yadin |
2. Issuer Name and Ticker or Trading Symbol Oramed Pharmaceuticals Inc. [ORMP] |
5. Relationship of Reporting Person(s) to Issuer (Check all applicable) ____ 10% Owner X |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| (Last) | (First) 1185 Avenue of the Americas |
(Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 01/04/2024 |
Director _ Officer (give title below)_ Other (specify below) |
||||||
| (Street) New York |
NY | 10036 | 4. If Amendment, Date Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person ____ Form filed by More than One Reporting Person |
||||||
| (City) | (State) | (Zip) | Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. |
| 1.Title of Security (Instr. 3) |
2. Transaction Date (Month/Day/Year) |
2A. Deemed Execution Date, if any (Month/Day/Year) |
3. Transaction Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) |
6. Ownership Form: |
7. Nature of Indirect Beneficial |
|||
|---|---|---|---|---|---|---|---|---|---|---|
| Code | V | Amount | (A) or (D) |
Price | (Instr. 3 and 4) | Direct (D) or Indirect (I) (Instr. 4) |
Ownership (Instr. 4) |
|||
| Common Stock | 01/04/2024 | A | 30,000 | A | (1) | 146,500 | D | |||
| Common Stock | 01/04/2024 | A | 8,820 | A | (2) | 155,320 | D |
| 1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security |
3. Transaction Date (Month/Day/Year) |
3A. Deemed Execution Date, if any (Month/Day/Year) |
4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or (D) (Instr. 3, 4, and 5) |
Disposed of | 6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Code | V | (A) | (D) | Date Exercisable |
Expiration Date |
Title | Amount or Number of Shares |
/s/ Yadin Rozov 01/08/2024
**Signature of Reporting Person Date
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.